VOICED : Sanofi y GSK comienzan a probar en seres humanos posible vacuna contra covid-19

Sanofi and GSK have initiated clinical trials for a potential COVID-19 vaccine, using technology previously applied to flu vaccines. The trials, involving 440 participants, aim to assess tolerance and immune response. If successful, the vaccine could be commercialized by the end of the year. The companies plan to produce up to 1 billion doses in 2021, with significant portions reserved by the EU, US, and UK. Additionally, they will contribute to COVAX for equitable distribution. Other vaccines, like those from Pfizer and Moderna, are in more advanced stages.

Which two companies have initiated clinical trials for a potential COVID-19 vaccine?

• Novavax and Sinovac

• Johnson & Johnson and AstraZeneca

• Sanofi and GSK

• Pfizer and Moderna

What is the main goal of the initial clinical trials conducted by Sanofi and GSK?

• To test the vaccine on animals

• To assess the vaccine's tolerance and immune response

• To determine the vaccine's market price

• To compare the vaccine with other COVID-19 vaccines

How many doses do Sanofi and GSK plan to produce in 2021 if the trials are successful?

• 100 million doses

• 2 billion doses

• 1 billion doses

• 500 million doses

Which organization is involved in the COVAX initiative to distribute COVID-19 vaccines?

• Food and Drug Administration

• Centers for Disease Control and Prevention

• World Health Organization

• European Medicines Agency

Which country has reserved the largest number of doses from Sanofi and GSK?

• Canada

• European Commission

• United Kingdom

• United States